Podcasts about kansas cancer center

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. Rebecca Whelan, an associate professor of chemistry at the University of Kansas and member of KU Cancer Center's Cancer Biology research program. The discussion focuses on the limitations of the CA125 blood test for ovarian cancer detection and Dr. Whelan's groundbreaking research, which reveals new insights into the structure of the CA125 protein. Dr. Whelan explains how new DNA sequencing technologies and artificial intelligence, specifically the Alpha Fold program, have helped her team improve the understanding and detection of ovarian cancer. Additionally, Dr. Whelan talks about collaborative efforts to identify new biomarkers for early diagnosis of ovarian cancer and shares advice for young scientists interested in making a difference in medicine through chemistry. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Whelan's research into CA125 Learn more about ovarian cancer  Read about ovarian cancer screening and diagnosis at KU Cancer Center Learn more about Dr. Rebecca Whelan

In this episode of the Bench to Bedside podcast Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses the critical topic of alcohol consumption and its link to cancer risk with Dr. Lauren Nye, medical oncologist at the cancer center and associate professor of Internal Medicine at the University of Kansas Medical Center. They delve into the recent advisory from the US Surgeon General highlighting the increased cancer risk associated with alcohol consumption, explore how alcohol can promote cancer development through various mechanisms, and offer practical advice for reducing alcohol intake. Dr. Nye underscores the importance of public awareness and the role of healthcare professionals in disseminating this information, while also emphasizing the need for sustainable lifestyle changes. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Read the US Surgeon General's Advisory “Alcohol and Cancer Risk” Read “Understanding Breast Cancer Prevention” by Dr. Lauren Nye on the KU Cancer Center blog Learn about cancer prevention and risk reduction on the KU Cancer Center website

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, is joined by Dr. Lisa Harlan-Williams, associate director for education at the cancer center, to discuss the variety of careers involved in the field of cancer care and research, beyond doctors and nurses. Dr. Harlan-Williams shares her own career path and talks about various initiatives at KU Cancer Center to attract and train for the oncology workforce. They highlight the importance of early exposure to different career opportunities and the educational programs available, including shadowing professionals and summer research internships. The discussion also touches on the growing demand for cancer care professionals due to increasing cancer cases and workforce shortages. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about educational opportunities and programs for students considering a career in cancer research at KU Cancer Center Learn about the Accelerate Cancer Education summer research program at KU Cancer Center Read about the C-CLEAR summer internship program at KU Cancer Center Learn more about the Jewell Summer Research Training Program at KU Cancer Center    

She was diagnosed with breast cancer in her early 30s. Her reality reflects the latest cancer statistics- younger women are being diagnosed with breast cancer. Hear her message for other young women about the importance of early detection. Guests include breast cancer survivor Alex Owens, breast cancer patient Emily Moritz, and Dr. Lindsay Kilgore, Breast Surgical Oncologist with The University of Kansas Cancer Center.

A German bone marrow transplant donor stepped up to save the life of a stranger. Their new bond turned into a special friendship. Guests include donor Silja Löw, Dr. Joseph McGuirk, division director hematologic malignancies and cellular therapeutics, The University of Kansas Cancer Center and Mindy Allen, lead blood and marrow transplant coordinator, The University of Kansas Cancer Center.

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, hosts Dr. Marc Hoffmann, associate professor specializing in Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center and medical director of the lymphoma program at KU Cancer Center, where he also serves as medical director for quality improvement initiatives. Beyond his clinical expertise, Dr. Hoffmann has contributed significantly to research in lymphoma and chronic lymphocytic leukemia (CLL), and he actively participates in national cooperative group clinical trials. Dr. Hoffmann shares his career path into the field of oncology, innovations in lymphoma and CLL treatments, as well as the unique aspects of KU Cancer Center's lymphoma program. The conversation also covers Dr. Hoffmann's Peace Corps experience in West Africa, his involvement in clinical trials, and advice for medical students interested in hematology and oncology. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the lymphoma program at KU Cancer Center Learn about chronic lymphocytic leukemia (CLL) Learn more about CAR T-cell therapy at KU Cancer Center Learn more about Dr. Marc Hoffmann Watch a video of Dr. Hoffmann explaining how blood cancer is diagnosed  

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, is joined by Dr. Andrew Godwin, director of KU Cancer Center's Biospecimen Shared Resource. They discuss the critical role that volunteers who donate biospecimens play in advancing cancer research. The podcast delves into the types of biospecimens collected, their use in medical studies, and how the KU Cancer Center's repository has grown to include over one million samples. Dr. Godwin shares insights on successful projects, including the Triple Negative Breast Cancer Registry and emerging technologies in biomarker analysis. He also emphasizes the importance of community participation in the biobank and offers advice for young investigators in the field of biomedical research. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode:  Learn more about KU Cancer Center's Biospecimen Shared Resource Learn how to donate to the KU BioBank Read more about how the Biospecimen Shared Resource supports the Early Detection Program within the KU BioBank Learn more about Dr. Andrew Godwin

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, engages in an insightful conversation with Dr. Robert Winn, Director and Lippman Chair in Oncology at Massey Comprehensive Cancer Center at Virginia Commonwealth University. They discuss Dr. Winn's pioneering work in cancer research and health equity, especially focusing on underserved communities. The episode highlights the significance of the Inclusive Excellence initiative Dr. Winn is leading as president of the American Association of Cancer Institutes (AACI), as well as disparities in cancer care in rural areas, the exciting advancements in immunotherapy and molecular therapies, and the essential role of trust and communication in healthcare. The dialogue underscores the critical need for appropriate investment in cancer research to continue making significant strides in reducing cancer mortality and improving patient outcomes. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Robert Winn Read about the AACI Inclusive Excellence initiative Learn about the National Cancer Institute and the designated cancer centers program

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHMF24).

In this special mini episode of the Bench to Bedside Podcast, Dr. Elizabeth Muenks, director of The University of Kansas Cancer Center's Onco-Psychology Program, addresses listener-submitted questions on managing the holiday season while navigating a loved one's cancer journey. The episode provides thoughtful advice on keeping loved ones involved without overwhelming them, adjusting holiday traditions to accommodate dietary restrictions and energy levels, and balancing caregiving responsibilities with holiday preparations. In this conversation, Dr. Muenks emphasizes the value of open conversations, giving oneself grace and seeking support during this emotionally challenging time. The episode concludes with practical tips for creating special, low-energy holiday activities suitable for cancer patients and their families. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode:  Learn more about Dr. Muenks Listen to Dr. Muenks in Bench to Bedside episode 20, “Coping with Cancer During the Holiday Season”

In this episode of the Bench to Bedside Podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses exciting advancements in the treatment of acute myeloid leukemia (AML) with Dr. Tara Lin, director of the adult leukemia program at KU Cancer Center and site principal investigator for myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice), a precision-medicine initiative sponsored by the National Cancer Institute (NCI). MyeloMATCH is an “umbrella trial,” a group of clinical substudies for people with acute myeloid leukemia or myelodysplastic syndrome. In this conversation Dr. Lin explains the challenges of AML, as well as the innovative aspects of the myeloMATCH trial, such as rapid diagnostic testing and specialized clinical trial options based on genetic and molecular features. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the myeloMATCH trial View the myleoMATCH trial on the NCI's clinical trials database Learn more about AML Read about clinical trials at KU Cancer Center Learn more about Dr. Tara Lin

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/FCS2024mTNBC).

In this poignant episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Cheryl Jernigan, Lead Patient Research Advocate with Patient and Investigator Voices Organizing Together (PIVOT). Cheryl shares her powerful story of being both a cancer survivor herself and a co-survivor and caregiver to her husband, who battled both prostate cancer and tonsil cancer caused by human papillomavirus (HPV). Their discussion explores the emotional and physical challenges of caregiving, the importance of research and patient advocacy, and the vital support systems needed for caregivers. Cheryl's experience offers invaluable insight into balancing personal health while providing care, highlighting resources such as Turning Point and Gilda's Club to aid caregivers on their journey. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about KU Cancer Center's patient research advocacy program, PIVOT Read Cheryl's blog post about PIVOT on the KU Cancer Center website Find cancer caregiver resources at KU Cancer Center Learn more about Turning Point's services for cancer patients and caregivers at KU Cancer Center  

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

In this podcast episode, we talk to Liz Muenks, a licensed psychologist and director of the Onco-Psychology Program at the University of Kansas Cancer Center. We discuss the psychosocial and emotional challenges faced by patients undergoing CAR T-cell therapy, a groundbreaking treatment for cancer, and how these experiences affect both patients and caregivers.Liz explains that patients typically enter CAR T-cell therapy after exhausting other treatment options, which leads to a heavy emotional burden. Many patients feel like they've "failed" previous treatments, a term that Liz finds problematic but acknowledges is often used. The pre-treatment phase is already filled with anxiety, depression, and fear. While some patients approach CAR T with hope and optimism, others carry a deep skepticism based on their past experiences. Liz notes that there are optimists, pessimists, and realists among patients, each bringing a different mindset to this journey.Liz highlights the societal pressure on cancer patients to maintain a positive attitude, which can add stress. She dispels the myth that a positive mindset is required to beat cancer, emphasizing that embracing all emotions, including fear and worry, is crucial to managing the cancer journey. While uncontrolled anxiety or depression can negatively impact outcomes, Liz reassures that patients can still succeed in their treatment even with emotional ups and downs.The conversation also touches on the unique side effects of CAR T-cell therapy, which differs from traditional treatments like bone marrow and stem cell transplants. While patients often feel relieved that the chemotherapy before CAR T is less intense, they are faced with neurological risks and the potential for serious side effects like cytokine release syndrome. However, these severe side effects affect a minority of patients.Caregivers, Liz stresses, play a vital role, especially as CAR T is increasingly being done on an outpatient basis. She advises caregivers to lean on their medical teams for support and never hesitate to ask questions. Caregivers often feel immense pressure, but Liz encourages them to recognize that they are not alone in this journey. Support networks include therapy groups, on line resources such as nbmtLINK.org (and many others) and on-call specialists , all available, offering caregivers support in sharing their burdens and finding reputable resources and guidance.Finally, Liz discusses the psychological challenges that linger after CAR T-cell therapy, especially the anxiety of cancer recurrence. Many patients struggle to move forward, constantly worrying about how much time they have before the disease returns. While some can compartmentalize these fears, others need ongoing psychological support. Liz also shares stories of patients who were initially hesitant about CAR T due to difficult past treatments but later experienced positive outcomes, reflecting the progress being made in this groundbreaking cancer therapy.This season is made possible thanks to our sponsors:Kite, a Gilead company: http://www.kitepharma.com/and Bristol Myers Squibb's CAR T support services program:https://www.celltherapy360.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/Or visit our website at https://www.nbmtlink.org/

Being overweight or having obesity is linked with a higher risk of getting 13 types of cancer. These cancers comprise 40% of all cancers diagnosed in the United States each year. In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Dr. John Thyfault, professor in the Department of Cell Biology and Physiology and in the Division of Endocrinology, Metabolism and Genetics, as well as director of the University of Kansas Diabetes Institute and co-leader of the Kansas Center for Metabolism and Obesity Research (KC-MORE), a new research hub based at the University of Kansas Medical Center to study human obesity and obesity-related disease. They discuss the significant impact of obesity on cancer incidence and mortality, as well as Dr. Thyfault's work developing translational research to improve patient outcomes. The discussion also explores how hormonal disruptions caused by obesity affect tumor growth, the potential of pharmacologic interventions like Ozempic, and the importance of maintaining physical activity and a healthy diet in cancer prevention and management. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about KC-MORE Read about KC-MORE's research into obesity and cancer Learn more about Dr. Thyfault

In this episode of the Bench to Bedside podcast Joseph Hines, II, MPH, senior director of research operations at The University of Kansas Cancer Center, joins Dr. Roy Jensen, vice chancellor and director, to discuss the launch and success of the CAREERS in CLINICAL RESEARCH PROGRAM (C-CLEAR Program). This groundbreaking initiative is designed to introduce college students in the region to the dynamic and impactful field of clinical research. Hines, along with students Mariah Slaughter, Hilary Tallman, and Angel Tchamnou, share their experiences and the program's impact on their understanding of clinical research and oncology. The conversation covers the program's objectives, the challenges of its inception, as well as the achievements of its first cohort. The students also offer advice for future participants and express gratitude towards their mentors. Future developments and application details for the program are also highlighted. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the C-CLEAR Program Watch “A Day in the Life” with the C-CLEAR student interns Learn more about high school and undergraduate programs at KU Cancer Center

This episode of ASTCT Talks dives into outpatient CAR T therapy, exploring logistics, challenges, and success strategies. Host Dr. Zahra Mahmoudjafari leads a panel of experts to share insights from their innovative programs. The panel features Robb Richards, Administrative Director of Cell Therapy and Transplant at Penn Medicine; Dr. Katie Gatwood, Clinical Pharmacy Specialist at Vanderbilt University Medical Center; and Dr. Taha Al-Juhaishi, Associate Director at the University of Oklahoma's Transplant and Cell Therapy Program. Topics include outpatient program structures, toxicity management, and the evolving role of cell therapies beyond hematologic malignancies. About the Host:Dr. Zahra Mahmoudjafari is a board-certified oncology pharmacist and Clinical Pharmacy Manager in Hematologic Malignancies at the University of Kansas Cancer Center. She earned her PharmD and MBA from UMKC and focuses on clinical and operational management of cell and gene therapies. Dr. Mahmoudjafari is active in HOPA, ATOPP, and ASTCT and was honored with ASTCT's Pharmacy SIG Lifetime Achievement Award and ASCO's 40 Under 40 in Cancer Award. Meet the Panel: Robb Richards has over 20 years of oncology experience, with roles spanning private practice, IT, and leadership in healthcare systems. At Penn Medicine, he oversees CAR T therapy operations, expanding services into community hospitals. He holds degrees from Drexel University and St. Joseph's University. Dr. Katie Gatwood is a Board-Certified Oncology Pharmacist at Vanderbilt University Medical Center, where she leads the PGY2 Oncology Residency Program and chairs the ASTCT Pharmacy SIG. Her expertise spans CAR T therapy, transplant conditioning, and GVHD therapies. Dr. Gatwood is an award-winning practitioner and has authored several publications on oncology pharmacy practice. Dr. Taha Al-Juhaishi is an attending physician and clinical investigator at OU Stephenson Cancer Center, Oklahoma's only NCI-designated center. He serves as associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy program and leads several clinical trials. Dr. Al-Juhaishi trained at Weill Cornell Medicine, VCU, and MD Anderson Cancer Center. Listeners will gain valuable insights into the complexities of managing outpatient CAR T therapy and strategies to enhance patient care.

Hear more about the use of AI in mammograms and how it is helping the future of healthcare. Guests include Onalisa Winblad, MD, director of breast imaging at The University of Kansas Cancer Center.

Approaching cancer from unique angles and perspectives is crucial for gaining an understanding of this disease and optimizing treatment strategies for patients. In the Department of Radiation Oncology at The University of Kansas Cancer Center, our specialists work to accelerate progress toward more personalized and effective ways to treat cancer through research and clinical trials. In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Dr. Xinglei Shen, associate professor in the Department of Radiation Oncology at the cancer center. Dr. Shen directs clinical research efforts in the Department of Radiation Oncology and in this episode, he highlights the significant technological advancements in radiation therapy over the past decade, including innovations like proton beam therapy and precision medicine. Dr. Shen also explains the diverse types of cancer research conducted at KU, the importance of patient advocacy in clinical trials, and his vision for the future of radiation oncology. Links from this Episode: Learn more about Proton Therapy at KU Cancer Center Dr. Xinglei Shen discusses the latest clinical trials and importance of patient-centered research on the KU Cancer Center blog Learn about the Department of Radiation Oncology at KU Cancer Center Follow the Department of Radiation Oncology on X (formerly Twitter) and Instagram

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASCO24/BreastCancer).

Colorectal cancer, also called colon cancer or rectal cancer, is one of the most treatable cancers when found early. However, it is also the most common type of gastrointestinal cancer and is the second leading cause of cancer deaths in the United States. For decades, colorectal cancer was most often diagnosed in people aged 50 and over. More recently, the incidence of colorectal cancer has declined in people 50 and over, while dramatically increasing in younger people. Because of this shift, the American Cancer Society recently revised its colorectal cancer screening guidelines for people at average risk. According to the updated guidelines, individuals at average risk of colorectal cancer should have regular screening for colon cancer beginning at age 45. On this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses this topic with Dr. John Ashcraft, Associate Professor of Surgery and Division Chief of the Colorectal & Oncologic Surgery Division at the University of Kansas Medical Center, and Dr. Raed Al-Rajabi, Associate Professor of medicine in the division of medical oncology and leader of the gastrointestinal medical oncology group at the University of Kansas Medical Center. Links from this Episode:  Read the new American Cancer Society guidelines for colon cancer screening Learn more about colon cancer screening and treatment at KU Cancer Center Read about Dr. Ajay Bansal's Lynch Syndrome research and clinic Learn more about Dr. John Ashcraft and Dr. Raed Al-Rajabi After listening to this episode, we invite YOU to be a part of the podcast! We want to hear your thoughts on the conversations we have here, topics you'd like to learn more about and any questions you may have for our guests. Call our Bench to Bedside hotline at 913-588-3880 and leave us a voicemail, or you can email your comments and questions to benchtobedside@kumc.edu. Your comments may be shared on a future episode!

On this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down for a conversation with Drs. Byron Gajewski and Devin Koestler, co-leaders of the Biostatistics and Informatics Shared Resource at KU Cancer Center. Just as a coach uses a playbook to strategize and make informed decisions during a game, researchers use biostatistics to analyze data and draw meaningful conclusions in their studies. On today's episode, Drs. Gajewski and Koestler share more about how the Biostatistics and Informatics Shared Resource supports KU Cancer Center's researchers by using examples from different sports teams.  In addition, they discuss their career journeys and give their advice and tips for anyone who may want to pursue a career in mathematics. Links from this Episode: -        Learn more about the Shared Resources at KU Cancer Center -        Read about the Biostatistics and Informatics Shared Resource at KU Cancer Center -        Learn about our Clinical Trials Finder App -        Learn more about Dr. Gajewski -        Learn more about Dr. Koestler  

On this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down for a conversation with Camy Crank, author of the book “Hair Today, Gone Tomorrow: What I Lost and Gained Through Breast Cancer.” Camy's own breast cancer journey began in 2015, when a second opinion from KU Cancer Center showed stage 3B disease. In 2020, she learned her cancer had metastasized. Camy is also a member of KU Cancer Center's patient research advocacy group, PIVOT, where she has been able to contribute to cancer research through providing the patient perspective. Listen as Camy shares her cancer journey, why writing about the experience was important to her and her family, and what she has learned along the way. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode:  Purchase Camy's book, "Hair Today, Gone Tomorrow: What I Lost and Gained Through Breast Cancer" Learn more about breast cancer screening at KU Cancer Center Learn more about cancer metastasis Become a member of PIVOT, KU Cancer Center's patient research advocacy program

Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/HER2PosTNBC).

Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.

The University of Kansas Cancer Center's Accelerate Cancer Education (ACE) program is a summer research program specifically designed for high school students living in Wyandotte County, Kansas and Jackson County, Missouri. The cancer center launched ACE in 2018 in collaboration with the University of Kansas Medical Center's Health Careers Pathways Programs and the NIH-funded Kansas Idea Network of Biomedical Research Excellence program. On this episode, Dr. Roy Jensen, vice chancellor and director of KU Cancer Center, speaks with Dr. Lisa Harlan-Williams, director of the ACE Program, about this innovative initiative. Also joining the conversation is one of our very first ACE graduates, Jesus Gonzalez Morales, who shares how the experience shaped his career aspirations and how ACE impacted his life. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about KU Cancer Center's ACE Program Learn about Dr. Lisa Harlan-Williams Watch this video where the 2022 ACE cohort and their mentors share some of their favorite memories from the program Read about another ACE graduate, Julie Gonzalez-Morales, in KU Cancer Center's annual report, Beyond the Bench

On this episode of the Bench to Bedside podcast, host Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks Dr. Simon Craddock Lee, interim associate director for Cancer Workforce Equity at the cancer center. Cancer is a leading cause of death in the United States, with a long track record of disproportionately affecting racial and ethnic minorities, gender and sexual minorities, rural groups and people with disabilities. The National Cancer Institute has recognized this problem and issued a call to action, specifically recognizing that Americans should share equally in advances in cancer research, and cancer disparities should be eliminated. One of the tools to reach this goal is to enhance diversity in the cancer workforce. Dr. Lee leads these efforts at KU Cancer center, in order to better represent the breadth of communities in our region experiencing cancer health disparities. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Simon Lee Learn more about cancer workforce equity efforts at KU Cancer Center Read about the NCI's National Cancer Plan and goal to optimize the cancer workforce

Each year in the United States, about 240,000 women and 2,100 men are diagnosed with breast cancer. The average risk of a woman in the United States developing breast cancer sometime in her life is about 13%. This means there is a 1 in 8 chance she will develop breast cancer, which is why breast cancer awareness and screening are so important. In May 2023, the United States Preventive Services Task Force (USPSTF) lowered the breast cancer screening age from 50 to 40 – but do these age screenings apply to everyone? What factors contribute to a high-risk classification for breast cancer, and how do we identify if we are at genetic risk? We spoke with Lauren Nye, MD, board-certified oncologist at the University of Kansas Cancer Center and Clinical Medical Director of Breast Cancer Prevention, about the importance of assessing your cancer risk, learning your genetic history, and prioritizing your overall health.

He used to play for the Chiefs. Now he's helping fight cancer...on a bike. You'll meet this player and a mom riding Coast to Coast to help her son fight cancer. Guests include Dr. Roy Jensen, vice chancellor and director, The University of Kansas Cancer Center.

Mothers and daughters usually like to share things, except when it comes to an unexpected diagnosis. Learn how this duo faced two very different diagnoses, but shared the same dream team when it came to their treatment. Guests include Dr. Joseph McGuirk, director, hematologic malignancies and cellular therapeutics; medical director, blood and marrow transplant, The University of Kansas Cancer Center; and Dr. Elizabeth Muenks, PhD, onco-psychologist, The University of Kansas Cancer Center.

Meet a man whose nationwide search for a prostate cancer cure led him to a unique treatment right here at home. Guests include Dr. Ronald Chen, radiation oncologist; chair, radiation oncology, The University of Kansas Cancer Center.

Doctors say he is their miracle patient, not expected to live even days longer. Yet years later he's thriving and starting his own family. You'll meet him and learn more about the life-saving immunotherapy that made it possible. Guests include Dr. Andrea Jewell, division director, gynecologic oncology, The University of Kansas Cancer Center.

Imagine- diagnosing your own cancer. That's how a young ultrasound tech discovered she had ovarian cancer. She shares her story, and the signs you need look out for. Guests include Dr. Andrea Jewell, division director, gynecologic oncology, The University of Kansas Cancer Center.

Meet a hero who followed through on a bone marrow donation commitment and how he saved a stranger's life. Guests include Dr. Sunil Abhyankar, hematologist with oncologist with The University of Kansas Cancer Center.

Brain surgery couldn't remove all of Lisa Webb's tumors, so she became the very first adult patient to get proton therapy at The University of Kansas Cancer Center. Find out how she's doing now that she has completed her treatment.

Patient Yolanda Irvin is a strong believer in getting a second opinion. She shares how she came to receive her care at the University of Kansas Cancer Center as well as her new mission in life. Guests include Dr. Anup Kasi, Dr. Mazin Al-Kasspooles and Dr. Jamie Wagner.

It's easy to shine a light on those who are considered to be cancer survivors. However, there are many patients who live with cancer. One patient shares his experience living with a terminal diagnosis. Why go through treatment? How do friends and family react? And what does hope mean in their situation? Guests include Dr. Doug Burton and Meredith Paulette, a nurse navigator working with brain tumor patients at The University of Kansas Cancer Center.

Only eight percent of people with this aggressive colorectal cancer survive. Learn how a daughter beat the odds and forever changed her bond with her dad. Dr. Guests include Stephanie Pfeil, colon cancer survivor, and Joaquina Baranda, medical oncologist, The University of Kansas Cancer Center.

Religious beliefs posed a challenge for treating a young woman diagnosed with leukemia since blood transfusions are not permitted for Jehovah's Witness followers. Doctors at The University of Kansas Cancer Center accepted the challenge with a treatment option that met both her medical and spiritual needs.

When standard chemotherapy wasn't working for one patient, a blend of two remarkable therapies – CAR-T and CRISPR – trained the immune system to exterminate the cancer. Guests include patient Katie Kopp and Dr. Joseph McGuirk, hematologist and medical oncologist and the Division Director of Hematologic Malignancies and Cellular Therapeutics at The University of Kansas Cancer Center.

A leader, a mentor, and a nationally acclaimed expert is the new leader of The University of Kansas Cancer Center. Meet the man who is leading innovative research and patient care. Guests include Dr. Roy Jensen, director and vice chair, The University of Kansas Cancer Center, and Dr. Jeff Holzbeierlein, new physician-in-chief, The University of Kansas Cancer Center; president, Society of Urologic Oncology, Inc.

We are profiling the 100th proton patient at The University of Kansas Cancer Center – a woman who had a complex tumor that was no problem for the new technology.

Learn about one of the first proton therapy patients at the University of Kansas Cancer Center. How did it work on non-cancerous tumors threatening his brain and spine? Guests include Dr. Raed Al-Rajabi and Dr. Ronny Rotondo.

Today my guest is Pathologist Dr Roy Jensen What we discuss with Dr Jensen: How he decided to go to medical school and how he chose a specialty Two of his mentors early in his career, and how he was influenced by them His research work in the BRCA1 and BRCA2 genes How he established a Cancer Center at the University of Kansas, and some of the work that goes into that Why he thinks being a pathologist helps him in this role The NCI designations for cancer centers and achieving his goal of Comprehensive Designation His thoughts on the future of cancer incidence Links for this episode: Health Podcast Network  LabVine Learning AGBT Precision Health Meeting The ConfLab from LabVine Dress A Med scrubs   To NCI designation through difficulty: How KU's Roy Jensen made it happen Dr. Roy Jensen of The University of Kansas Cancer Center: Innovating to Break Cancer's Grip University of Kansas Cancer Center   People of Pathology Podcast: Website Twitter

Leadership is a journey, not a destination. In this episode, Joel sits down with the brains and unrelenting passion behind a truly remarkable achievement nearly two decades in the making. Joining him is Dr. Roy Jensen, a brilliant pathologist, widely published scientific authority and the Director of the University of Kansas Cancer Center. His vision put Kansas City on the map, medically speaking, and was a process he will admit was no walk in the park. With persistence, he led the effort in earning our region its first ever NCI designation, a major success in itself. But there was still room to become even better. Under Dr. Jensen's tireless guidance, the University is now well on its way to becoming a comprehensive cancer center, a rare appointment reserved for the most elite. He's on the cusp of the ultimate achievement, and only time will tell what he accomplishes next.